UNSPSC 51333704: Tetrabenazine

This classification denotes a dopamine antagonist with the molecular formula C19H27NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z9O08YRN8O, chemically known as 1,3,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy-2h-benzo(a)quinolizin-2-one but generally known as tetrabenazine, which bears US NIH Compound Identifier 6018. European Medicines Agency schedules Tetrabenazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10939MIG. The term TETRABENAZINE is an International Non-Proprietary Name.

UNSPSC 51333704 Tetrabenazine is a Commodity code that captures individual pharmaceutical products procured by state and local health systems, but the recent opportunities tagged under it do not reflect tetrabenazine purchases specifically. Instead, the recent activity shows state and local governments buying naloxone and drug deactivation systems, generic multi-source pharmaceuticals through cooperative purchasing vehicles, and evaluating direct-to-manufacturer pharmacy programs. The issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving multiple states including Oregon). The mix reflects both direct county procurement and centralized cooperative purchasing models used by multiple jurisdictions to aggregate pharmaceutical demand and negotiate pricing.

Recent opportunities span Florida, Texas, Minnesota, and Oregon. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023, and quarterly deliveries to the county's community health building. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, signaling state-level interest in alternative pharmaceutical supply-chain models. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026, and contract effectiveness of July 1, 2026. MMCAP's approach requires vendors to work through authorized wholesalers and imposes a 3 percent administrative fee on all purchases. The code shows minimal direct activity in tetrabenazine procurement and substantial activity in broader pharmaceutical supply and cooperative purchasing arrangements.